ATE547098T1 - Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt - Google Patents

Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt

Info

Publication number
ATE547098T1
ATE547098T1 AT07735308T AT07735308T ATE547098T1 AT E547098 T1 ATE547098 T1 AT E547098T1 AT 07735308 T AT07735308 T AT 07735308T AT 07735308 T AT07735308 T AT 07735308T AT E547098 T1 ATE547098 T1 AT E547098T1
Authority
AT
Austria
Prior art keywords
oral formulation
cardiovascular effects
activity
beneficial cardiovascular
berberine
Prior art date
Application number
AT07735308T
Other languages
English (en)
Inventor
Paolo Senin
Ivo Setnikar
Luigi Angelo Rovati
Original Assignee
Rottapharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Spa filed Critical Rottapharm Spa
Application granted granted Critical
Publication of ATE547098T1 publication Critical patent/ATE547098T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT07735308T 2006-03-30 2007-03-29 Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt ATE547098T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000239A ITTO20060239A1 (it) 2006-03-30 2006-03-30 Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare
PCT/IB2007/051109 WO2007113748A1 (en) 2006-03-30 2007-03-29 Oral formulation with beneficial cardiovascular effects, comprising berberine

Publications (1)

Publication Number Publication Date
ATE547098T1 true ATE547098T1 (de) 2012-03-15

Family

ID=38421558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07735308T ATE547098T1 (de) 2006-03-30 2007-03-29 Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt

Country Status (9)

Country Link
US (1) US9623108B2 (de)
EP (1) EP2007429B1 (de)
AT (1) ATE547098T1 (de)
DK (1) DK2007429T3 (de)
ES (1) ES2382115T3 (de)
IT (1) ITTO20060239A1 (de)
PL (1) PL2007429T3 (de)
PT (1) PT2007429E (de)
WO (1) WO2007113748A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110670B2 (en) 2006-05-19 2012-02-07 Ls9, Inc. Enhanced production of fatty acid derivatives
US20100242345A1 (en) 2006-05-19 2010-09-30 LS9, Inc Production of fatty acids & derivatives thereof
CN102027109B (zh) 2008-05-16 2016-01-06 Reg生命科学有限责任公司 产生碳氢化合物的方法和组合物
ITMI20081403A1 (it) 2008-07-29 2010-01-30 Velleja Res Srl Composizioni comprendenti berberina e/o suoi analoghi o estratti che la contengano, per la prevenzione e il trattamento delle alterazioni del quadro lipidico e glucidico
WO2010062480A2 (en) 2008-10-28 2010-06-03 Ls9, Inc. Methods and compositions for producing fatty alcohols
EP2405755A4 (de) * 2009-03-11 2012-11-28 Xintria Pharmaceutical Corp Inc Verfahren und zusammensetzungen zur behandlung von stoffwechsel- und herz-kreislauf-erkrankungen
CN111808892A (zh) 2009-04-27 2020-10-23 基因组股份公司 脂肪酸酯的产生
FR2950061B1 (fr) 2009-09-11 2013-12-20 Coatex Sas Monomeres associatifs a base de polycosanols, epaississants associatifs correspondants et leurs utilisations
KR101307051B1 (ko) 2011-05-20 2013-09-11 강릉원주대학교산학협력단 미세조류 단백질 가수분해물을 포함하는 콜레스테롤 강하용 조성물
ITMI20121696A1 (it) * 2012-10-09 2014-04-10 Ddf Group S A S Composizioni per il trattamento delle iperlipidemie
ITMI20130241A1 (it) 2013-02-21 2014-08-22 Andrea Rondi Composizione per il trattamento di disordini metabolici
ITUB20150541A1 (it) 2015-03-03 2016-09-03 Acraf Composizione comprendente sostanze e/o estratti naturali
US10434131B2 (en) 2015-03-16 2019-10-08 Nature's Sunshine Products, Inc. Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations
EP3117825A1 (de) * 2015-07-16 2017-01-18 Rottapharm S.p.A. Orale formulierung mit berberin und morus-alba-extrakt
IT201900020316A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Uso di berberina sucrosomiale® e sue composizioni nel trattamento di alterazioni del metabolismo glucidico
IT201900020300A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Uso di berberina sucrosomiale® e sue composizioni nel trattamento di dislipidemie
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use
IT201900020290A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Berberina sucrosomiale®, sue composizioni e loro uso
IT202200008537A1 (it) * 2022-04-29 2023-10-29 Neilos S R L “Composizione nutraceutica o farmaceutica per la salute cardiovascolare”
IT202200008534A1 (it) * 2022-04-29 2023-10-29 Neilos S R L “Composizione nutraceutica o farmaceutica per la salute cardiovascolare”
DE202023106947U1 (de) 2023-11-23 2024-01-10 Supett Laboratories Limited Zusammensetzung umfassend Panthenol, PQQ und Quercetin zur Vorbeugung von Herzkrankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952393A (en) 1998-02-12 1999-09-14 Sorkin, Jr.; Harlan Lee Composition for reducing serum cholesterol levels
US6436406B1 (en) 2000-06-15 2002-08-20 A. Glenn Braswell Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
AUPR510001A0 (en) * 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
WO2003020260A1 (en) 2001-08-31 2003-03-13 Metaproteomics, Llc Arginine compositions for coordinate modification of multiple cardiovascular risk factors
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
ITTO20040682A1 (it) * 2004-10-07 2005-01-07 Rottapharm S R L Formulazione per somministrazione orale avente un effetto salutistico sull'apparato cardiovascolare

Also Published As

Publication number Publication date
EP2007429B1 (de) 2012-02-29
US20090136469A1 (en) 2009-05-28
WO2007113748A1 (en) 2007-10-11
PT2007429E (pt) 2012-04-12
PL2007429T3 (pl) 2012-07-31
ES2382115T3 (es) 2012-06-05
DK2007429T3 (da) 2012-05-29
EP2007429A1 (de) 2008-12-31
US9623108B2 (en) 2017-04-18
ITTO20060239A1 (it) 2007-09-30

Similar Documents

Publication Publication Date Title
ATE547098T1 (de) Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
AU2013334740A8 (en) Stable, low viscosity antibody formulation
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EA201001285A1 (ru) Применение 25-oh d3 для воздействия на физиологию мышц человека
EP3878445A3 (de) Acamprosat-formulierungen, verfahren zur verwendung davon und kombinationen damit
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
WO2011116220A3 (en) Oral supplement
CY1108314T1 (el) Σκευασμα για στοματικη χορηγηση εχοντας μια δραση που προαγει την υγεια επι του καρδιαγγειακου συστηματος
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
WO2012145575A3 (en) Therapy for leukemia
WO2010041832A3 (ko) 패 유래 화합물 함유 항산화 활성 조성물
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
CL2012003250A1 (es) Uso de un galactolipido en combinacion con acido ascorbico y/o un derivado del mismo que sirve para proteger una composicion contra la oxidacion; metodo para la preparacion de la composicion, composicion; y producto.
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
IN2014DN10134A (de)
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
WO2013173803A3 (en) Formulations of amoxicillin and clavulanate potassium and methods for using same
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
WO2011092655A3 (en) Mentha suaveolens essential oil and therapeutic activities thereof
WO2012134167A3 (ko) 비파엽 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
MY184940A (en) Lignosus rhinocerus (tiger-milk mushroom) as anti-inflammatory agent
WO2008090850A1 (ja) 抗癌剤の効果増強剤
IN2013MU01330A (de)